Osteogenesis imperfecta: lifelong management is imperative and feasible (Q34233595)

31 July 2017

1 reference

title

Osteogenesis imperfecta: lifelong management is imperative and feasible (English)

1 reference

31 July 2017

main subject

osteogenesis imperfecta

0 references

author name string

Chevrel G

series ordinal

1

1 reference

31 July 2017

Meunier PJ

series ordinal

2

1 reference

31 July 2017

publication date

1 March 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

68

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

125-129

1 reference

Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Genetic heterogeneity in osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Images in clinical medicine. Blue sclerae in osteogenesis imperfecta.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Mutation analysis of coding sequences for type I procollagen in individuals with low bone density

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Extension of phenotype associated with structural mutations in type I collagen: siblings with juvenile osteoporosis have an alpha2(I)Gly436 --> Arg substitution.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Causes of death in osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Spinal deformity, pulmonary compromise, and quality of life in osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Static and dynamic bone histomorphometry in children with osteogenesis imperfecta.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Bone density in osteogenesis imperfecta may well be normal

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Bone mineral content and density in healthy subjects and in osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Hypercalciuria in children severely affected with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Hypercalciuria in osteogenesis imperfecta: a follow-up study to assess renal effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Is APD a promising drug in the treatment of severe osteogenesis imperfecta?

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Intravenous pamidronate treatment in osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Osteogenesis imperfecta after the menopause

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2801%2900256-1

7 January 2021

10.1016/S1297-319X(01)00256-1

Identifiers

DOI

1 reference

31 July 2017

1 reference